Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine

Objective: To evaluate fremanezumab quarterly or monthly vs placebo on health-related quality of life, health status, patients’ global impression of change, and productivity in patients with chronic migraine (CM). Methods: HALO CM was a double-blind, placebo-controlled trial in patients with CM. Patients were randomized 1:1:1 to treatment with fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (225 mg at baseline, weeks 4 and 8), or placebo. This manuscript assessed the effect of treatment with fremanezumab on health-related quality of life and productivity using the following prespecified assessments: the Migraine-Specific Quality of Life (MSQoL) questionnaire at baseline, weeks 4, 8, 12; Patient Global Impression of Change (PGIC) questionnaire at weeks 4, 8, 12; EuroQoL 5-dimension, 5-response level (EQ-5D-5L) questionnaire and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire at baseline and week 12. Results: The full analysis set included 1121 patients: 375 patients with quarterly dosing, 375 with monthly dosing, and 371 with placebo. Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p Conclusions: Fremanezumab quarterly or monthly was associated with improvement over placebo in migraine-specific quality of life, overall health status, patients’ global impression of change with treatment, and productivity in patients with CM.